GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE85020 Query DataSets for GSE85020
Status Public on Jul 31, 2017
Title Epigenetic silencing of the tumor suppressor RASSF4 favors multiple myeloma progression
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary RAS is frequently mutated in multiple myeloma (MM) leading to aberrant signaling. Next to their classical oncogenic effects, RAS proteins also mediate anti-tumor effects through the Ras-Association Domain Family (RASSF) proteins. Currently, no data about the role of RASSF proteins in MM disease is available. Here we report that RASSF4 is downregulated during MM progression, correlating with a bad prognosis. Epigenetic modulating agents significantly increased RASSF4 expression, indicating that the RASSF4 downregulation is due to epigenetic silencing. Forced RASSF4 expression induced a G2-phase arrest and caspase-3 mediated apoptosis in human MM cell lines, strongly reduced viability of primary CD138+ MM cells and significantly reduced in vivo tumor growth. Moreover, we demonstrated RASSF4-MST1 binding and the involvement of the downstream signaling pathways JNK/Jun, p38 and p53. RASSF4 overexpression sensitized MM cells to the proteasome inhibitor bortezomib, the specific MEK1/2 inhibitor trametinib and the ROS inducer Prima-1Met. Consequently, combining trametinib with histone deacetylase inhibitors (HDACi) revealed very strong synergistic anti-MM activity. In conclusion, our study identified RASSF4 as a new potent tumor suppressor in MM that is epigenetically silenced during MM progression and provides the basis for novel therapeutic strategies enhancing RASSF4 expression (using HDACi) in combination with MEK/ERK inhibitors and bortezomib.
Overall design Paired-end RNA sequencing analysis of the RASSF4 transduced cell lines cultured for 5 days in the presence of doxycycline
Contributor(s) De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Heirman C, Maes A, Hose D, Breckpot K, Van Grunsven L, Moreaux J, De Bruyne E
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Aug 01, 2016
Last update date May 15, 2019
Contact name Jerome Moreaux
Organization name CHRU Montpellier
Department Biological Hematology
Lab Laboratory for Monitoring Innovative Therapies
Street address 80 Av. Augustin Fliche
City Montpellier
ZIP/Postal code 34295
Country France
Platforms (1)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
Samples (6)
GSM2256384 AMO1 RASSF4 control vector
GSM2256385 AMO1 overexpressing RASSF4
GSM2256386 JJN3 RASSF4 control vector
BioProject PRJNA335945
SRA SRP080734

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE85020_count_normalized_dseq2.txt.gz 1.4 Mb (ftp)(http) TXT
GSE85020_raw_count.txt.gz 1.3 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Processed data are available on Series record
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap